Outcomes of blinatumomab based therapy in children with relapsed, persistent, or refractory acute lymphoblastic leukemia: a multicenter study focusing on predictors of response and post-treatment immunoglobulin production

References

• Jastaniah W, Essa MF, Ballourah W, et al. Incidence trends of childhood acute lymphoblastic leukemia in Saudi Arabia: Increasing incidence or competing risks? Cancer Epidemiol. 2020;67:101764. doi:10.1016/j.canep.2020.101764.
   PubMed Web of Science ®Google Scholar
• Al-Sudairy R, Al-Nasser A, Alsultan A, et al. Clinical characteristics and treatment outcome of childhood acute lymphoblastic leukemia in Saudi Arabia: a multi-institutional retrospective national collaborative study. Pediatr Blood Cancer. 2014;61(1):74–80. doi:10.1002/pbc.24584.
   PubMed Web of Science ®Google Scholar
• Seibel NL, Steinherz PG, Sather HN, et al. Early post-induction intensification therapy improves survival for children and adolescents with high-risk acute lymphoblastic leukemia: a report from the Children’s Oncology Group. Blood 2008;111(5):2548–2555. doi:10.1182/blood-2007-02-070342.
   PubMed Web of Science ®Google Scholar
• Pui C-H, Sandlund JT, Pei D, et al. Total Therapy Study XIIIB at St. Jude Children’s Research Hospital. Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children’s Research Hospital. Blood 2004;104(9):2690–2696. doi:10.1182/blood-2004-04-1616.
   PubMed Web of Science ®Google Scholar
• von Stackelberg A, Völzke E, Kühl J-S, et al. Outcome of children and adolescents with relapsed acute lymphoblastic leukaemia and non-response to salvage protocol therapy: a retrospective analysis of the ALL-REZ BFM Study Group. Eur J Cancer Oxf Engl. 2011;47(1):90–97. doi:10.1016/j.ejca.2010.09.020.
   PubMed Web of Science ®Google Scholar
• Parker C, Waters R, Leighton C, et al. Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial. Lancet Lond Engl. 2010;376(9757):2009–2017. doi:10.1016/S0140-6736(10)62002-8.
   PubMed Web of Science ®Google Scholar
• Mustafa O, Abdalla K, AlAzmi AA, Elimam N, Abrar MB, Jastaniah W. FLAG/FLAG-IDA regimen for children with relapsed/refractory acute leukemia in the era of targeted novel therapies. J Oncol Pharm Pract. 2019;25(8):1831–1838. doi:10.1177/1078155218817816.
   PubMed Web of Science ®Google Scholar
• Halford Z, Coalter C, Gresham V, Brown T. A systematic review of blinatumomab in the treatment of acute lymphoblastic leukemia: engaging an old problem with new solutions. Ann Pharmacother. 2021;55(10):1236–1253. doi:10.1177/1060028020988411.
   PubMed Web of Science ®Google Scholar
• von Stackelberg A, Locatelli F, Zugmaier G, et al. Phase I/phase II study of blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia. JCO. 2016;34(36):4381–4389. doi:10.1200/JCO.2016.67.3301.
   PubMed Web of Science ®Google Scholar
• Gore L, Locatelli F, Zugmaier G, et al. Survival after blinatumomab treatment in pediatric patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia. Blood Cancer J. 2018;8(9):80–90. doi:10.1038/s41408-018-0117-0.
   PubMed Web of Science ®Google Scholar
• Keating AK, Gossai N, Phillips CL, et al. Reducing minimal residual disease with blinatumomab prior to HCT for pediatric patients with acute lymphoblastic leukemia. Blood Adv. 2019;3(13):1926–1929. doi:10.1182/bloodadvances.2018025726.
   PubMed Web of Science ®Google Scholar
• Gökbuget N, Dombret H, Bonifacio M, et al. Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia. Blood 2018;131(14):1522-1531. 2019;133(24):2625–2625. doi:10.1182/blood.2019001109.
   PubMed Web of Science ®Google Scholar
• Brown PA, Ji L, Xu X, et al. Effect of postreinduction therapy consolidation with blinatumomab vs chemotherapy on disease-free survival in children, adolescents, and young adults with first relapse of B-cell acute lymphoblastic leukemia: a randomized clinical trial. JAMA. 2021;325(9):833–842. doi:10.1001/jama.2021.0669.
   PubMed Web of Science ®Google Scholar
• Lee DW, Santomasso BD, Locke FL, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019;25(4):625–638. doi:10.1016/j.bbmt.2018.12.758.
   PubMed Web of Science ®Google Scholar
• Locatelli F, Zugmaier G, Mergen N, et al. Blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia: results of the RIALTO trial, an expanded access study. Blood Cancer J. 2020;10(7):77 doi:10.1038/s41408-020-00342-x.
   PubMed Web of Science ®Google Scholar
• Wei AH, Ribera J-M, Larson RA, et al. Biomarkers associated with blinatumomab outcomes in acute lymphoblastic leukemia. Leukemia 2021;35(8):2220–2231. doi:10.1038/s41375-020-01089-x.
   PubMed Web of Science ®Google Scholar
• Locatelli F, Zugmaier G, Rizzari C, et al. Effect of blinatumomab vs chemotherapy on event-free survival among children with high-risk first-relapse B-cell acute lymphoblastic leukemia: a randomized clinical trial. JAMA. 2021;325(9):843–854. doi:10.1001/jama.2021.0987.
   PubMed Web of Science ®Google Scholar
• Diorio C, Maude SL. CAR T cells vs allogeneic HSCT for poor-risk ALL. Hematol Am Soc Hematol Educ Program. 2020;2020(1):501–507. doi:10.1182/hematology.2020000172.
   PubMedGoogle Scholar
• Mejstríková E, Hrusak O, Borowitz MJ, et al. CD19-negative relapse of pediatric B-cell precursor acute lymphoblastic leukemia following blinatumomab treatment. Blood Cancer J. 2017;7(12):659 doi:10.1038/s41408-017-0023-x.
   PubMed Web of Science ®Google Scholar
• Stelmach P, Wethmar K, Groth C, et al. Blinatumomab or inotuzumab ozogamicin as bridge to allogeneic stem cell transplantation for relapsed or refractory B-lineage acute lymphoblastic leukemia: a retrospective single-center analysis. Clin Lymphoma Myeloma Leuk. 2020;20(10):e724–e733. doi:10.1016/j.clml.2020.05.022.
   PubMed Web of Science ®Google Scholar
• Maude SL. Tisagenlecleucel in pediatric patients with acute lymphoblastic leukemia. Clin Adv Hematol Oncol HO. 2018;16(10):664–666.
   PubMed Web of Science ®Google Scholar
• McNeer JL, Rau RE, Gupta S, Maude SL, O’Brien MM. Cutting to the front of the line: immunotherapy for childhood acute lymphoblastic leukemia. Am Soc Clin Oncol Educ Book. 2020;40:1–12. doi:10.1200/EDBK_278171.
   PubMedGoogle Scholar
• Clesham K, Rao V, Bartram J, et al. Blinatumomab for infant acute lymphoblastic leukemia. Blood 2020;135(17):1501–1504. doi:10.1182/blood.2019004008.
   PubMed Web of Science ®Google Scholar
• Stein AS, Schiller G, Benjamin R, et al. Neurologic adverse events in patients with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab: management and mitigating factors. Ann Hematol. 2019;98(1):159–167. doi:10.1007/s00277-018-3497-0.
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Stein A, Gökbuget N, et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med. 2017;376(9):836–847. doi:10.1056/NEJMoa1609783.
   PubMed Web of Science ®Google Scholar
• Zugmaier G, Topp MS, Alekar S, et al. Long-term follow-up of serum immunoglobulin levels in blinatumomab-treated patients with minimal residual disease-positive B-precursor acute lymphoblastic leukemia. Blood Cancer J. 2014;4(9):244 doi:10.1038/bcj.2014.64.
   PubMedGoogle Scholar